Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections

Abstract

A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans , and multidrug resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam lysinate delivered as an aerosol or dry powder formulation.

1 - 36  (canceled) 
     
     
         37 . A method of treating a pulmonary bacterial infection in a human comprising administering an inhalable composition comprising aztreonam lysinate, wherein the human has cystic fibrosis. 
     
     
         38 . The method of  claim 37  wherein the pulmonary bacterial infection  Pseudomonas aeruginosa.    
     
     
         39 . The method of  claim 38  wherein the inhalable composition comprising aztreonann lysinate is administered three times a day.